Sunday, February 19, 2023 12:19:50 AM
Not if they thread the needle right. There could be unblindable data to see that could be used with extended follow up of test persons medical histories since the trial testing went on hold, that shows that Placebos got Long haul Covid and none of the Bucillamine dosed folks got long Covid. That would require the rest of the data, and test people follow up of their outcomes long term... and some elbow grease and horse trading with the FDA, or just get the all data and after trial case history, publish it, and sell out to Pfizer for 10 Billion dollars?
That may be part of what all the horse trading with the FDA is all about. It would be, if it was me...
That may be part of what all the horse trading with the FDA is all about. It would be, if it was me...
Bullish
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
